和黄医药GSK特别电话会议：AX30海外授权及ATTC平台进展

发布时间：2026-09-03 一、AI总结内容 一、核心交易与战略 1. 和黄医药与GSK达成AX30中国区授权合作，属共同开发交易，和黄负责AX30全球I期开发，GSK负责I期后中国区开发。2. AX30总交易规模约13亿美元，含1.1亿美元首付款，后续将获分级特许权使用费；AX30为全球首个Kras-EGFR抗体偶联（ADTC）前临床资产。3. 本次合作验证和黄医药ADTC平台价值，将加速AX30全球开发、拓展适应症机会，同时丰富GSK肿瘤管线，其ADTC布局从ADC延伸至ADTC。 二、核心产品AX30科学特性与价值 1. AX30为Kras-EGFR双靶点ADTC，以EGFR抗体为载体，同时靶向Kras突变与EGFR过表达，Kras突变约占人类癌症的30%，常见于结直肠癌、胰腺癌、肺癌等实体瘤。 2. AX30优势：双靶点阻断可克服单一Kras抑制剂产生的EGFR上游旁路耐药；精准递送payload降低正常组织全身毒性，可实现更优安全性与疗效；支持与化疗、免疫疗法联用，拓展早期治疗组合潜力。3. AX30为和黄ADTC平台核心验证资产，后续该平台还将推进PI3K、HER2等靶点项目（A251、A580）。 三、近期管线进展与商业安排 1. 和黄与阿斯利康合作的两款产品III期临床均获阳性结果，PFS、OS数据将在学术会议公布，全球销售可获9%-13%分级特许权使用费，预计1/3 EGFR耐药患者将受益于该联合疗法。2. 中国区现有3款产品已商业化，和黄将从阿斯利康处获30%特许权使用费，后续MRTX扩增、EGFR突变患者适应症获批后，将覆盖一线治疗。四、Q&A核心要点 1. AX30临床推进计划：I期将纳入Kras突变的结直肠癌、胰腺癌、肺癌等患者，早期启动与化疗、免疫疗法的联合研究，目标推进至一线治疗。 2. GSK合作起源：GSK本身已有上市及在研ADTC产品，AX30契合其下一代ADTC布局，和黄与多家跨国药企均有合作接触，本次为ADTC平台的部分合作。 3. GSK针对和黄另一款早期ADTC候选产品拥有优先谈判权，和黄同时与其他跨国药企就平台其他项目保持沟通，后续合作进展将按规定披露。 二、音频原文（转写） 对。Good morning, good afternoon and good eveningeveryone. Welcome to Hutchmet's special webcastfollowing our announcement earlier today of theBD transaction with GSK. I'm Frederick Chan fromHutchmet Investor Relations and I'm pleased tomoderate today's discussion. Before we begin, please rename your display name in a format of org anization full of your name. This is going to help us to identify participants during the Q&A. Please note. are with safe harbor statement and disclaimer. The performance and results of operation of the Hutchmet group contain within its organization, within its presentation of historicalin nature and past performance is not a guarantee of future results. Joining us today from Hushmanagement team are Dr. Dan Elder, Chairman andnon executive director. Mr. Johnny Chan, actingchief executive officer and chief financial officer. And Dr. Guangxiou Dai. executive vice president, head of discovery and global portfolio management. Without further ado, it is my pleasureto invite Dr Alda to deliver opening remarks. miss out a piece. 嗯。 Ken, I think you are on mute. Thank you, friends. Today's agreement with GSK clearly embodies Hutchmet's strategic vision to build a globally competitive oncology portfolio. encouraged by differentiated innovation. centered around the firstclass novel. ATTC Pay with platform assets. with meaningful combination potential. with standards of care for earlier line. treatments. ESK isa leading biopharma company world class multinational partner. with a global development reach and expertise to maximize. the potential of. HMPA. eight three いいよね。 The strategy of Hatchmet is to generate that platform which can produce a number of drug candidates. using ai. and the appearance. accumulated by many years. of drug discovery developments andproduction. We understand that we cannot bringall our candidates to global markets by using internal resources only. and therefore, which is the best strategy to maximize the value of each ATPC drug candidate. At times. We shall maintainall rights. At other times, we intend to. License, excellent. China writes knowing that an excel lent partner like GSK. as the ability to accelerate development. Sometimes you would see us embarking on joint development and sometimes licensing global rights. This partnership we announcedtoday is another validation and acceleration ofinternational access that is central to our strategy. It also demonstrates how we can create themost significant shareholders' value as well asthe greatest impact on the lives of patients globally. Thank you. Fred, please proceed. Thank you, Chairman. And the next Johnny, please. Okay,thank you, Fred, and thank you, Chairman, for sharing your vision and view of this platform andalso the direction of the company. So now we just have a quick highlight of the key terms of this transaction. Our AX30 is a first-in-class preclinical asset. which is a K Ross EGFR antibodyconjugate. We are licensing A X thirty X China rights. to gsk This is a co-development deal in which Hugmet will be responsible for the global Phase 1 development and GSK will take over the ExChina development post Phase I. the total dealsize. it's around US dollar one point three billion. including upfront of 110 million. And oncecommercialized, Hutchback will receive tiered royalties. the benefits of parchment in doing thisdeal is that we can accelerate the global development of AIX-30, and unlock multiple indicationopportunities. As mentioned by our chairman. This also serves to validate our ATTC platform. byreputable multinational company. A switch yes k. This transaction will expand the global oncology reach. as well as extend their expertise in this area. It also enriches and advances their next generation R&D portfolio from a d c to a t tc. I will now pass to Dr. Dai to share with youall the details of A830. Thank you, Johnny. Andthank everyone for your time today. While K-Riceis a key protein that drives cell growth. Whenmutated, it causes cells to divide uncontrollably, leading to